RxDoctor Payments Data

Shashidhar Divakaruni, MD

Interventional Cardiology · Munster, INNPI 1902936578

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $63,755 of the $96,643 with a category attached, or 66.0%. Johnson & Johnson accounts for 72.5% of it on its own, with 51 other manufacturers making up the rest. Reporting peaked in 2019 at $37,794 and has fallen 93.5% since, to $2,441 in 2025. Among interventional cardiology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$96,643in general payments, 2019–2025

Across 744 payments — averaging $129.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$70K
  • Medtronic$5K
  • Cardiovascular Systems Inc.$3K
  • Boston Scientific$2K
  • Philips North America LLC$2K
  • Amgen$1K
  • plus $12K from 46 others

What the payments were for

  • Consulting fees$3080%
  • Speaking & faculty fees$63,75566%
  • Travel & lodging$7,8688%
  • Food & beverage$24,60725%
  • Education$780%
  • Other$280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$96,643 in reported general payments places this provider in the 95th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$432,808
Medicare patients
857
Services billed
4,818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban177$242,919
EntrestoSacubitril/Valsartan161$182,439
EliquisApixaban101$104,875
JardianceEmpagliflozin27$35,305
FarxigaDapagliflozin Propanediol29$29,186
Isosorbide Mononitrate ErIsosorbide Mononitrate959$20,666
OzempicSemaglutide12$18,209
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$15,004
Prasugrel Hcl90$12,205
Carvedilol1,127$8,207
Amiodarone Hcl146$6,238
ClopidogrelClopidogrel Bisulfate503$5,526
Ranolazine ErRanolazine56$5,037
Metoprolol Succinate228$4,820
MresviaRsv Vaccine, Pref, Mrna/Pf13$3,856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$70,056$242,919177 claims
NovartisEntresto$1,229$182,439161 claims
PfizerEliquis$227$104,875101 claims
Boehringer IngelheimJardiance$280$35,30527 claims
AstraZenecaFarxiga$997$29,18629 claims
Novo NordiskOzempic$242$18,20912 claims
GSKTrelegy Ellipta$29$15,00421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →